camostat (QAU145) / Novartis - LARVOL DELTA

Biden Administration Invests $3 Billion in Developing Antiviral COVID-19 Pill (Verywell Health) - "'Currently the only respiratory virus that can be treated is influenza, Geoffrey Chupp, MD...tells Verywell. 'There are multiple approved antiviral medications for HIV, hepatitis B, adenovirus, and CMV, so it's perfectly reasonable to expect that we can develop effective antivirals against SARS-CoV-2.'...'It appears that variants will continue to emerge and that people around the world will continue to get infected,' Chupp says. 'Limiting the severity of illness and shortening the recovery will be important for years until it is clear the virus is no longer a threat. Swine flu is still an issue after 100 years.'"

Media quote • Novel Coronavirus Disease

ACTG Adds Four Promising New Therapies to ACTIV-2 Outpatient Treatment Study (Newswise) - "Camostat, provided by Sagent Pharmaceuticals (a Nichi-Iko Group Company), is an orally administered protease inhibitor that will be dosed as 200 mg every six hours for seven days. Camostat inhibits TMPRSS2, a host cell protease that facilitates SARS-CoV-2 binding and entry into the host cell. Participants will take the first dose of Camostat at enrollment and subsequent doses at home. The study is being led by...and Nikolaus Jilg, M.D...ACTIV-2 is led by...Dr. Wohl...and ACTG Co-Chair Joseph J. Eron, M.D..."

Novel Coronavirus Disease

Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. (PubMed, Pharmacol Ther) - "Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine...We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system."

Clinical • Journal • Review • Infectious Disease • Novel Coronavirus Disease

Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. (PubMed, Front Pharmacol) - "Initial candidate interventions include prophylaxis to augment epithelial defense (e.g., AT1 receptor blockade, type III and type I interferons, melatonin, calcitriol, camostat, and lopinavir) and to reduce viral load (e.g., remdesivir, ivermectin, emetine, Abelson kinase inhibitors, dopamine D2 antagonists, and selective estrogen receptor modulators). Additional interventions focus on tempering inflammatory signaling and injury (e.g., dexamethasone, doxycycline, Ang1-7, estradiol, alpha blockers, and DHA/EPA, pasireotide), as well as inhibitors targeted toward molecular mediators of the maladaptive COVID-19 immune response (e.g., IL-6, TNF-α, IL-17, JAK, and CDK9)."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombosis • ANGPT1 • IL17A • IL6 • TMPRSS2

Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients (clinicaltrials.gov) - P2; N=360; Not yet recruiting; Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

New P2 trial • Diabetes • Genetic Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Obesity

Long-term observation of cases of chronic kidney disease (CKD) with negative urinary protein (first report) (JSN 2020) - "There were 61 (90%) in the stopped group, 2 (3%) in the ascending group, and 5 (7%) in the decreasing group. The salt intake (g/day) and protein intake (g/StWtkg/day) determined by 24hUC were widely distributed in all three groups, and there was no constant tendency. [Discussion/Conclusion] In urinary protein-negative CKD, 93% were in the cessation or elevation group and 7% in the reduction group."

Clinical • Chronic Kidney Disease • Nephrology • Renal Disease

COPS-2002: Oral Camostat Compared With Standard Supportive Care in Mild COVID-19 Patients (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Stanford University

New P2 trial • Infectious Disease • Novel Coronavirus Disease

"200mg HCQ, Brombexine 3x8mg TMPRSS2 same as Camostat" (@sunrainmakerain)

TMPRSS2